Peptomyc S.L., founded in December 2014 and based in Barcelona, Spain, focuses on developing innovative cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company's approach is grounded in extensive scientific research, particularly the work on Omomyc, recognized as a leading Myc inhibitor. With global cancer incidence exceeding 14 million cases annually and projected to rise significantly, Peptomyc aims to address the limitations of conventional therapies, which often fail due to resistance. By targeting the Myc oncoprotein, which plays a critical role in cancer cell survival and is deregulated in many cancers, Peptomyc seeks to offer a promising therapeutic option where none currently exist. The company is particularly focused on developing treatments for lung, breast, and brain tumors, thereby enhancing the potential for improved patient survival outcomes.
Mediktor Corp. is a B2B MedTech company that specializes in developing an advanced medical symptom checking platform. Founded in 2011 and headquartered in Barcelona, Spain, with an additional office in New York, the company offers an AI-based medical device designed for triage, pre-diagnosis, and decision-making support. Mediktor's application is accessible across multiple interfaces, including iOS, Android, the web, and Amazon Alexa, and supports various languages. The platform is clinically validated and aims to enhance healthcare accessibility by enabling patients to make informed decisions based on their symptoms. Additionally, it assists healthcare providers, including hospitals, insurance companies, and pharmaceutical laboratories, in optimizing resources and improving medical coverage through efficient demand management. The tool integrates artificial intelligence and natural language processing to analyze patient data, detect symptoms, and provide potential conditions and recommendations, thereby facilitating timely and cost-effective healthcare decisions.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.
Inbiomotion SL, a personalized medicine company, develops biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company focuses on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. It develops biomarker in breast cancer primary tumors for predicting the risk of bone relapse. Inbiomotion SL was founded in 2010 and is based in Barcelona, Spain.
Peptomyc S.L., founded in December 2014 and based in Barcelona, Spain, focuses on developing innovative cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company's approach is grounded in extensive scientific research, particularly the work on Omomyc, recognized as a leading Myc inhibitor. With global cancer incidence exceeding 14 million cases annually and projected to rise significantly, Peptomyc aims to address the limitations of conventional therapies, which often fail due to resistance. By targeting the Myc oncoprotein, which plays a critical role in cancer cell survival and is deregulated in many cancers, Peptomyc seeks to offer a promising therapeutic option where none currently exist. The company is particularly focused on developing treatments for lung, breast, and brain tumors, thereby enhancing the potential for improved patient survival outcomes.
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.
Accure Therapeutics S.L. develops, produces, and markets pharmaceutical drugs for the treatment of diseases related to central nervous system. The company is based in Barcelona, Spain.
SANIFIT is a biotechnology company focused on treatments for calcification disorders.
SANIFIT started activities in 2007 and has now operations in Spain and Switzerland.
Mediktor Corp. is a B2B MedTech company that specializes in developing an advanced medical symptom checking platform. Founded in 2011 and headquartered in Barcelona, Spain, with an additional office in New York, the company offers an AI-based medical device designed for triage, pre-diagnosis, and decision-making support. Mediktor's application is accessible across multiple interfaces, including iOS, Android, the web, and Amazon Alexa, and supports various languages. The platform is clinically validated and aims to enhance healthcare accessibility by enabling patients to make informed decisions based on their symptoms. Additionally, it assists healthcare providers, including hospitals, insurance companies, and pharmaceutical laboratories, in optimizing resources and improving medical coverage through efficient demand management. The tool integrates artificial intelligence and natural language processing to analyze patient data, detect symptoms, and provide potential conditions and recommendations, thereby facilitating timely and cost-effective healthcare decisions.
Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.
Peptomyc S.L., founded in December 2014 and based in Barcelona, Spain, focuses on developing innovative cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company's approach is grounded in extensive scientific research, particularly the work on Omomyc, recognized as a leading Myc inhibitor. With global cancer incidence exceeding 14 million cases annually and projected to rise significantly, Peptomyc aims to address the limitations of conventional therapies, which often fail due to resistance. By targeting the Myc oncoprotein, which plays a critical role in cancer cell survival and is deregulated in many cancers, Peptomyc seeks to offer a promising therapeutic option where none currently exist. The company is particularly focused on developing treatments for lung, breast, and brain tumors, thereby enhancing the potential for improved patient survival outcomes.